Resources

An alum-adjuvanted recombinant protein vaccine is administered intramuscularly to stimulate both innate and adaptive arms of immunity. The antigen depot releases 15.0 μg15.0\,\mu\mathrm{g} of viral glycoprotein monomer (molar mass M=7.50×104 g/molM = 7.50 \times 10^4\text{ g/mol}) into an effective interstitial drainage volume of 2.50 mL2.50\text{ mL}. (a) Calculate the initial molar concentration (CC) of the antigen in the local interstitial space. (b) Dendritic cells uptake this antigen via receptor-mediated endocytosis, degrade it within acidic endolysosomes (pH ≈4.8\approx 4.8), and present the fragments on MHC-II\text{MHC-II} molecules to naive CD4+\text{CD4}^+ T cells. Concurrently, the alum adjuvant binds to the intracellular NLRP3\text{NLRP3} sensor, triggering caspase-1 cleavage of pro-IL-1β\text{IL-1}\beta into active IL-1β\text{IL-1}\beta. Explain how this coupled innate inflammatory signaling directly enables the dendritic cell to license CD4+\text{CD4}^+ T-cell activation, citing the specific costimulatory surface molecules upregulated.

Answer and steps

Final answer

(a) Total moles of antigen =15.0×10−6 g7.50×104 g/mol=2.00×10−10 mol= \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol}; C=2.00×10−10 mol2.50×10−3 L=8.00×10−8 mol/L=8.00×10−8 MC = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ mol/L} = 8.00 \times 10^{-8}\text{ M} (or 80.0 nM80.0\text{ nM}). (b) NLRP3\text{NLRP3} inflammasome activation produces mature IL-1β\text{IL-1}\beta, which acts in an autocrine/paracrine manner to induce dendritic cell maturation. This upregulates the essential costimulatory ligands CD80\text{CD80} (B7-1) and CD86\text{CD86} (B7-2) on the dendritic cell membrane, which bind to CD28\text{CD28} on naive CD4+\text{CD4}^+ T cells (delivering 'Signal 2'), preventing T-cell anergy and ensuring full clonal activation.

Steps

Part (a): Calculating the Initial Molar Concentration of the Antigen

  1. Convert the given mass into grams and volume into liters:

    • Mass of viral glycoprotein, m=15.0 μg=15.0×10−6 gm = 15.0\text{ }\mu\text{g} = 15.0 \times 10^{-6}\text{ g}
    • Molar mass, M=7.50×104 g/molM = 7.50 \times 10^4\text{ g/mol}
    • Interstitial volume, V=2.50 mL=2.50×10−3 LV = 2.50\text{ mL} = 2.50 \times 10^{-3}\text{ L}
  2. Calculate the amount of substance (moles, nn): n=mM=15.0×10−6 g7.50×104 g/mol=2.00×10−10 moln = \frac{m}{M} = \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol}
  3. Determine the molar concentration (CC): C=nV=2.00×10−10 mol2.50×10−3 L=8.00×10−8 mol/L=8.00×10−8 M(or 80.0 nM)C = \frac{n}{V} = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ mol/L} = 8.00 \times 10^{-8}\text{ M}\quad (\text{or } 80.0\text{ nM})

Part (b): Mechanism of Dendritic Cell Licensing and CD4+\text{CD4}^+ T-Cell Activation

  1. Role of the Innate Danger Signal (NLRP3 Inflammasome):

    • Highly purified recombinant protein antigens lack intrinsic pathogen-associated molecular patterns (PAMPs\text{PAMPs}). Without an adjuvant, uptake of the protein by an antigen-presenting cell (APC\text{APC}) leads to immune tolerance or anergy rather than protective activation.
    • The aluminum hydroxide (alum) adjuvant acts as a danger signal: it destabilizes lysosomes or promotes uric acid/reactive oxygen species release, triggering the assembly of the intracellular NLRP3\text{NLRP3} inflammasome.
    • Active caspase-1 cleaves pro-IL-1β\text{IL-1}\beta into biologically active mature IL-1β\text{IL-1}\beta.
  2. Dendritic Cell Maturation and Phenotypic Shift:

    • Secreted IL-1β\text{IL-1}\beta signals in an autocrine and paracrine manner via IL-1R\text{IL-1R}, initiating downstream NF-κB\text{NF-}\kappa\text{B} signaling cascades.
    • This signal drives dendritic cell (DC\text{DC}) maturation, shifting the cell from an antigen-capturing state to an antigen-presenting state.
  3. Upregulation of Costimulatory Molecules:

    • Maturation drastically upregulates the surface expression of key costimulatory ligands: CD80\text{CD80} (also known as B7-1\text{B7-1}) and CD86\text{CD86} (also known as B7-2\text{B7-2}).
  4. Two-Signal Licensing of Naive CD4+\text{CD4}^+ T Cells:

    • Signal 1 (Antigen-Specific Signal): Peptide fragments loaded onto MHC-II\text{MHC-II} molecules bind to the T-cell receptor (TCR\text{TCR}) and its CD4\text{CD4} coreceptor on a naive T cell.
    • Signal 2 (Costimulatory Signal): The upregulated CD80\text{CD80} and CD86\text{CD86} ligands bind to CD28\text{CD28} receptors on the naive CD4+\text{CD4}^+ T cell.
    • Delivering both Signal 1 and Signal 2 simultaneously prevents clonal anergy (functional inactivation) and drives productive T-cell survival, IL-2\text{IL-2} secretion, proliferation, and differentiation into functional helper T cells (TH1\text{T}_\text{H}1 or TH2\text{T}_\text{H}2).

Typical errors

OverviewACEpath Teacher's Diagnosis

01 The student forgets to convert micrograms to grams, resulting in a calculated molar concentration that is off by a factor of 10^6.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    m=15.0 g  ⟹  n=15.07.50×104=2.00×10−4 molm = 15.0\text{ g} \implies n = \frac{15.0}{7.50 \times 10^4} = 2.00 \times 10^{-4}\text{ mol}

    Correct

    m=15.0 μg=15.0×10−6 g  ⟹  n=15.0×10−6 g7.50×104 g/mol=2.00×10−10 molm = 15.0\text{ }\mu\text{g} = 15.0 \times 10^{-6}\text{ g} \implies n = \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol}

    You treated the mass as 15.0 g15.0\text{ g} instead of converting from micrograms (15.0 μg=15.0×10−6 g15.0\text{ }\mu\text{g} = 15.0 \times 10^{-6}\text{ g}). Because the molar mass is given in g/mol\text{g/mol}, the mass must be in grams before dividing.

  2. Step 2

    V=2.50×10−3 L  ⟹  C=2.00×10−4 mol2.50×10−3 L=0.0800 MV = 2.50 \times 10^{-3}\text{ L} \implies C = \frac{2.00 \times 10^{-4}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 0.0800\text{ M}

    Correct

    V=2.50×10−3 L  ⟹  C=2.00×10−10 mol2.50×10−3 L=8.00×10−8 M (or 80.0 nM)V = 2.50 \times 10^{-3}\text{ L} \implies C = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ M}\text{ (or }80.0\text{ nM)}

    Your volume conversion and concentration formula are completely correct, but your final numerical value carried over the incorrect number of moles from Step 1.

  3. Step 3

    NLRP3 activation and active IL-1β stimulate dendritic cell maturation.  ⟹  This upregulates the costimulatory surface molecules CD80 and CD86.  ⟹  CD80/CD86 bind to CD28 on naive CD4+ T cells to provide costimulatory signal 2, enabling full T-cell activation.\text{NLRP3 activation and active IL-1}\beta\text{ stimulate dendritic cell maturation.} \implies \text{This upregulates the costimulatory surface molecules CD80 and CD86.} \implies \text{CD80/CD86 bind to CD28 on naive CD4}^+\text{ T cells to provide costimulatory signal 2, enabling full T-cell activation.}

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly identified and applied the formulas n=mMn = \frac{m}{M} and C=nVC = \frac{n}{V}.

You converted the volume from milliliters to liters without error.

You clearly explained the two-signal licensing model, specifically naming CD80\text{CD80}, CD86\text{CD86}, and CD28\text{CD28}.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Unit conversion omission (micrograms to grams)

You copied the numerical value 15.015.0 directly as grams without multiplying by 10−610^{-6} for the micro ( μ–\,\mu\text{--}) prefix.

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

Overlooking the metric prefix symbol μg\mu\text{g} when transferring given values into algebraic formulas where standard base units (grams) are required by molar mass (MM in g/mol\text{g/mol}).

REASONING PATH
Your ACEpath teacher’s suggested approach
Match units to standard constants
  • Molar mass is expressed in g/mol\text{g/mol}, requiring mass to be in grams (g\text{g}).

  • Always convert metric sub-units immediately: 1 μg=10−6 g1\text{ }\mu\text{g} = 10^{-6}\text{ g} and 1 mg=10−3 g1\text{ mg} = 10^{-3}\text{ g}.

Order-of-magnitude sanity check
  • Protein vaccines typically generate nanomolar (nM\text{nM}) to micromolar (μM\mu\text{M}) local concentrations.

  • A concentration of 0.08 M0.08\text{ M} is physiological for small ions like sodium, but impossibly high for a high-molecular-weight glycoprotein in a 2.5 mL2.5\text{ mL} depot.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Convert mass: m=15.0 μg=15.0×10−6 gm = 15.0\text{ }\mu\text{g} = 15.0 \times 10^{-6}\text{ g}.

  2. Calculate moles: n=15.0×10−6 g7.50×104 g/mol=2.00×10−10 moln = \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol}.

  3. Compute concentration: C=2.00×10−10 mol2.50×10−3 L=8.00×10−8 M=80.0 nMC = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ M} = 80.0\text{ nM}.

Final answer

(a) C=8.00×10−8 MC = 8.00 \times 10^{-8}\text{ M} (or 80.0 nM80.0\text{ nM}); (b) NLRP3\text{NLRP3}-derived IL-1β\text{IL-1}\beta induces dendritic cell maturation, upregulating CD80\text{CD80} and CD86\text{CD86}, which engage CD28\text{CD28} on CD4+\text{CD4}^+ T cells to deliver Signal 2.

NEXT STEPS
Final Takeaways from Your Teacher
  • Write out unit conversions explicitly as your first line of calculation before plugging values into n=m/Mn = m/M.

  • Check that biological concentrations for macromolecules fall in realistic ranges (usually pM\text{pM} to μM\mu\text{M}).

  • Review practice problems combining metric prefix conversions with molarity calculations in biomedical contexts.

OverviewACEpath Teacher's Diagnosis

02 The student confuses the costimulatory ligands CD80/CD86 on dendritic cells with the T-cell coinhibitory/exhaustion receptor PD-1 or CTLA-4.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    m=15.0×10−6 g  ⟹  n=15.0×10−6 g7.50×104 g/mol=2.00×10−10 mol  ⟹  V=2.50×10−3 L  ⟹  C=2.00×10−10 mol2.50×10−3 L=8.00×10−8 Mm = 15.0 \times 10^{-6}\text{ g} \implies n = \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol} \implies V = 2.50 \times 10^{-3}\text{ L} \implies C = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ M}

  2. Step 2

    Inflammasome signaling drives dendritic cell maturation.

  3. Step 3

    This causes the dendritic cell to upregulate PD-1 on its membrane surface to activate CD4+ T cells. PD-1 engagement delivers signal 2 for licensing naive CD4+ T cells.

    Correct

    Maturation induces upregulation of the costimulatory ligands CD80\text{CD80} (B7-1) and extCD86 ext{CD86} (B7-2) on the dendritic cell, which bind CD28\text{CD28} on naive CD4+\text{CD4}^+ T cells to deliver Signal 2.

    You named PD-1\text{PD-1} as the activating costimulatory molecule. PD-1\text{PD-1} (Programmed Cell Death Protein 1) is an inhibitory checkpoint receptor found primarily on T cells that dampens immune responses, whereas dendritic cells upregulate the costimulatory ligands CD80\text{CD80} (B7-1) and CD86\text{CD86} (B7-2) to engage CD28\text{CD28} on naive T cells.

WHAT YOU DID WELL
Compliments from Your Teacher

You executed the metric unit conversions and molar concentration formula flawlessly in Part (a).

You correctly linked adjuvant-mediated inflammasome activation to dendritic cell maturation in Part (b).

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Confusing Costimulatory Ligands with Inhibitory Checkpoint Receptors

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You confused the activating costimulatory ligands on antigen-presenting cells (CD80/CD86) with the coinhibitory checkpoint receptor (PD-1) that terminates T-cell responses.

REASONING PATH
Your ACEpath teacher’s suggested approach
Signal 2 Costimulation vs. Checkpoint Inhibition
  • Full naive T-cell activation requires Signal 1 (TCR−MHC\text{TCR}-\text{MHC}) and positive Signal 2 (CD80/CD86\text{CD80}/\text{CD86} on APCs\text{APCs} binding CD28\text{CD28} on T cells). In contrast, PD-1\text{PD-1} and CTLA-4\text{CTLA-4} deliver coinhibitory signals that suppress T-cell activation.

  • Always verify whether the molecule promotes clonal expansion (positive costimulation via B7:CD28\text{B7}:\text{CD28}) or halts activation/induces exhaustion (negative checkpoint inhibition via PD-1:PD-L1\text{PD-1}:\text{PD-L1} or CTLA-4:B7\text{CTLA-4}:\text{B7}).

Cellular Localization of Ligands vs. Receptors
  • CD80\text{CD80} and CD86\text{CD86} are surface ligands expressed on antigen-presenting cells (dendritic cells, macrophages, B cells), whereas CD28\text{CD28} and PD-1\text{PD-1} are receptors expressed on T lymphocytes.

  • When asked what an antigen-presenting cell upregulates upon maturation, look for ligands like CD80\text{CD80}, CD86\text{CD86}, or MHC-II\text{MHC-II}, not T-cell surface receptors.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Mature dendritic cells upregulate the costimulatory ligands CD80\text{CD80} (B7-1) and CD86\text{CD86} (B7-2) on their cell surface.

  2. These B7 molecules engage the costimulatory receptor CD28\text{CD28} constitutively expressed on naive CD4+\text{CD4}^+ T cells.

  3. This interaction delivers Signal 2, which acts alongside Signal 1 (peptide-loaded MHC-II\text{MHC-II} binding the TCR\text{TCR}) to prevent anergy and drive productive T-cell proliferation and cytokine secretion.

Final answer

(a) 8.00×10−8 M8.00 \times 10^{-8}\text{ M} (or 80.0 nM80.0\text{ nM}). (b) Active IL-1β\text{IL-1}\beta derived from the NLRP3\text{NLRP3} inflammasome stimulates dendritic cell maturation, upregulating the costimulatory ligands CD80\text{CD80} (B7-1) and CD86\text{CD86} (B7-2). These ligands bind to CD28\text{CD28} on naive CD4+\text{CD4}^+ T cells, delivering the necessary Signal 2 that licenses full T-cell activation and prevents anergy.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the 'Two-Signal Hypothesis' of T-cell activation, paying close attention to which molecule is on the antigen-presenting cell versus the T cell.

  • Create a comparison table contrasting positive costimulatory pairs (such as CD80/CD86 to CD28) with coinhibitory checkpoint pairs (such as PD-L1 to PD-1 and CD80/CD86 to CTLA-4).

OverviewACEpath Teacher's Diagnosis

03 The student confuses MHC classes and states that NLRP3-driven signaling switches presentation to MHC-I and CD80/CD86 to activate cytotoxic CD8+ T cells instead of licensing CD4+ T cells.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    m=15.0×10−6 g  ⟹  n=15.0×10−6 g7.50×104 g/mol=2.00×10−10 mol  ⟹  V=2.50×10−3 L  ⟹  C=2.00×10−10 mol2.50×10−3 L=8.00×10−8 Mm = 15.0 \times 10^{-6}\text{ g} \implies n = \frac{15.0 \times 10^{-6}\text{ g}}{7.50 \times 10^4\text{ g/mol}} = 2.00 \times 10^{-10}\text{ mol} \implies V = 2.50 \times 10^{-3}\text{ L} \implies C = \frac{2.00 \times 10^{-10}\text{ mol}}{2.50 \times 10^{-3}\text{ L}} = 8.00 \times 10^{-8}\text{ M}

  2. Step 2

    IL-1β signaling causes dendritic cells to switch antigen display from MHC-II to MHC-I.\text{IL-1}\beta\text{ signaling causes dendritic cells to switch antigen display from MHC-II to MHC-I.}

    Correct

    NLRP3 inflammasome activation generates mature IL-1β, which acts in an autocrine/paracrine manner to induce dendritic cell maturation while retaining presentation of the endocytosed protein fragments on MHC-II.\text{NLRP3 inflammasome activation generates mature }\text{IL-1}\beta\text{, which acts in an autocrine/paracrine manner to induce dendritic cell maturation while retaining presentation of the endocytosed protein fragments on MHC-II.}

    Adjuvant-induced IL-1β\text{IL-1}\beta signaling stimulates dendritic cell maturation, but it does not switch exogenous endolysosomal antigen presentation from MHC-II to MHC-I.

  3. Step 3

    Upregulation of CD80 and CD86 on the dendritic cell interacts with CD8+ T cells to license cytotoxic T-cell killing instead of CD4+ T-cell help.\text{Upregulation of CD80 and CD86 on the dendritic cell interacts with }\text{CD8}^+\text{ T cells to license cytotoxic T-cell killing instead of }\text{CD4}^+\text{ T-cell help.}

    Correct

    Upregulated CD80 (B7-1) and CD86 (B7-2) bind to CD28 on naive CD4+ T cells to deliver Signal 2, preventing anergy and ensuring productive helper T-cell activation.\text{Upregulated CD80 (B7-1) and CD86 (B7-2) bind to CD28 on naive }\text{CD4}^+\text{ T cells to deliver Signal 2, preventing anergy and ensuring productive helper T-cell activation.}

    You correctly identified the costimulatory molecules CD80 and CD86, but their upregulation functions to engage CD28 on naive CD4+\text{CD4}^+ T cells alongside the MHC-II/TCR interaction (Signal 1), preventing anergy rather than diverting the response away from helper T cells.

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly calculated the moles of recombinant protein and the resulting initial molar concentration in part (a).

You correctly identified CD80 and CD86 as the costimulatory ligands upregulated during dendritic cell activation.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
MHC pathway and T-cell licensing confusion

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You confused the MHC-II/CD4+ helper pathway with the MHC-I/CD8+ cytotoxic pathway, assuming that innate adjuvant signaling redirects exogenous antigen presentation toward cytotoxic killing rather than providing the second costimulatory signal needed to license helper T-cell activation.

REASONING PATH
Your ACEpath teacher’s suggested approach
Exogenous vs. Endogenous Antigen Routing
  • Proteins acquired by endocytosis and digested in acidic endolysosomes are loaded onto MHC-II molecules to stimulate CD4+\text{CD4}^+ T cells; they do not require or cause a switch to MHC-I.

  • Keep exogenous soluble subunit vaccine antigens paired with MHC-II presentation unless a cross-presentation scenario specifically directed at cytosolic entry is described.

The Two-Signal Model of T-Cell Activation
  • Signal 1 is peptide-MHC-II binding to the TCR/CD4 complex. Signal 2 is costimulatory ligand binding (CD80/CD86 to CD28), which prevents anergy and licenses full CD4+\text{CD4}^+ T-cell proliferation and cytokine secretion.

  • Pair CD80 and CD86 upregulation directly with CD28 binding on naive CD4+\text{CD4}^+ T cells to explain productive activation and adjuvant action.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. State that NLRP3 inflammasome assembly cleaves pro-IL-1β\text{IL-1}\beta into active IL-1β\text{IL-1}\beta, which promotes dendritic cell maturation without altering the MHC-II presentation pathway of endocytosed protein fragments.

  2. Explain that maturation upregulates surface CD80 (B7-1) and CD86 (B7-2).

  3. Describe how CD80/CD86 bind to CD28 on naive CD4+\text{CD4}^+ T cells to supply Signal 2, cooperating with MHC-II/TCR Signal 1 to achieve full activation and clonal expansion while preventing anergy.

Final answer

(a) C=8.00×10−8 MC = 8.00 \times 10^{-8}\text{ M} (or 80.0 nM80.0\text{ nM}). (b) IL-1β\text{IL-1}\beta produced via NLRP3 activation stimulates autocrine/paracrine dendritic cell maturation, upregulating costimulatory molecules CD80 and CD86. These molecules bind CD28 on naive CD4+\text{CD4}^+ T cells to provide Signal 2, which complements the MHC-II antigen presentation (Signal 1) and licenses productive CD4+\text{CD4}^+ T-cell activation without inducing anergy.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the two-signal hypothesis for naive T-cell activation, noting how Signal 1 (MHC-peptide + TCR) and Signal 2 (CD80/CD86 + CD28) collaborate.

  • Contrast the MHC-I (endogenous/cytosolic, CD8+\text{CD8}^+) and MHC-II (exogenous/endosomal, CD4+\text{CD4}^+) pathways to avoid conflating helper and cytotoxic activation pathways in subunit vaccine design.

Lock it in

Similar question

01

A recombinant subunit vaccine contains 20.0 μg20.0\text{ }\mu\text{g} of an antigen with molar mass M=4.00×104 g/molM = 4.00 \times 10^4\text{ g/mol}. It is dissolved in a total vial volume of 0.500 mL0.500\text{ mL}. Calculate the molar concentration (CC) of the antigen in the vial in nanomolar (nM\text{nM}).

Answer

m=20.0×10−6 g=2.00×10−5 gm = 20.0 \times 10^{-6}\text{ g} = 2.00 \times 10^{-5}\text{ g}. Moles n=2.00×10−5 g4.00×104 g/mol=5.00×10−10 moln = \frac{2.00 \times 10^{-5}\text{ g}}{4.00 \times 10^4\text{ g/mol}} = 5.00 \times 10^{-10}\text{ mol}. Volume V=5.00×10−4 LV = 5.00 \times 10^{-4}\text{ L}. C=5.00×10−10 mol5.00×10−4 L=1.00×10−6 M=1000 nMC = \frac{5.00 \times 10^{-10}\text{ mol}}{5.00 \times 10^{-4}\text{ L}} = 1.00 \times 10^{-6}\text{ M} = 1000\text{ nM}.

02

An adjuvant nanoparticle formulation releases 4.50 ng4.50\text{ ng} of an inflammatory cytokine (molar mass M=1.50×104 g/molM = 1.50 \times 10^4\text{ g/mol}) into a lymph node follicle of volume 15.0 μL15.0\text{ }\mu\text{L}. Calculate the resulting local molar concentration.

Answer

m=4.50×10−9 gm = 4.50 \times 10^{-9}\text{ g}. Moles n=4.50×10−9 g1.50×104 g/mol=3.00×10−13 moln = \frac{4.50 \times 10^{-9}\text{ g}}{1.50 \times 10^4\text{ g/mol}} = 3.00 \times 10^{-13}\text{ mol}. Volume V=15.0×10−6 L=1.50×10−5 LV = 15.0 \times 10^{-6}\text{ L} = 1.50 \times 10^{-5}\text{ L}. Concentration C=3.00×10−13 mol1.50×10−5 L=2.00×10−8 M=20.0 nMC = \frac{3.00 \times 10^{-13}\text{ mol}}{1.50 \times 10^{-5}\text{ L}} = 2.00 \times 10^{-8}\text{ M} = 20.0\text{ nM}.

03

During dendritic cell maturation triggered by adjuvant signaling, the cell downregulates endocytic receptor expression while dramatically upregulating MHC-II and costimulatory ligands. Explain why this functional shift is essential for efficient activation of naive T cells in the draining lymph node.

Answer

Downregulating endocytosis prevents the dendritic cell from acquiring new, irrelevant self-antigens during transit. Upregulating MHC-II (Signal 1) and CD80/CD86 (Signal 2) optimizes the cell's surface phenotype for stable immunological synapse formation with naive T cells, ensuring clonal activation rather than tolerance.

Loading workspace…